Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.

MLA

Utsunomiya, Masako, et al. “Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: Results from a Non-Blinded, Randomized Controlled Trial.” Arthritis Research & Therapy, vol. 19, no. 1, Jan. 2017, p. 7. EBSCOhost, https://doi.org/10.1186/s13075-016-1206-8.

APA

Utsunomiya, M., Dobashi, H., Odani, T., Saito, K., Yokogawa, N., Nagasaka, K., Takenaka, K., Soejima, M., Sugihara, T., Hagiyama, H., Hirata, S., Matsui, K., Nonomura, Y., Kondo, M., Suzuki, F., Tomita, M., Kihara, M., Yokoyama, W., Hirano, F., … Harigai, M. (2017). Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Research & Therapy, 19(1), 7. https://doi.org/10.1186/s13075-016-1206-8

Chicago

Utsunomiya, Masako, Hiroaki Dobashi, Toshio Odani, Kazuyoshi Saito, Naoto Yokogawa, Kenji Nagasaka, Kenchi Takenaka, et al. 2017. “Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: Results from a Non-Blinded, Randomized Controlled Trial.” Arthritis Research & Therapy 19 (1): 7. doi:10.1186/s13075-016-1206-8.